according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2024/09/28 7942506-00009 Date of first issue: 2021/03/19 4.0

1. PRODUCT AND COMPANY IDENTIFICATION

Oxfendazole / Oxyclozanide Formulation Product name

Manufacturer or supplier's details

Company MSD

Address No. 485 Jing Tai Road

Pu Tuo District - Shanghai - China 200331

Telephone +1-908-740-4000

Emergency telephone number: 86-571-87268110

E-mail address EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use Veterinary medicine Restrictions on use Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance : powder

Colour white to off-white, light cream, cream

Odour No data available

May damage fertility. May damage the unborn child. May cause damage to organs. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

GHS Classification

Reproductive toxicity Category 1B

Specific target organ toxicity - : Category 2

single exposure

Specific target organ toxicity - : Category 2

repeated exposure

Short-term (acute) aquatic Category 1

hazard

Long-term (chronic) aquatic Category 1

hazard

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

GHS label elements

Hazard pictograms





Signal word : Danger

Hazard statements : H360FD May damage fertility. May damage the unborn child.

H371 May cause damage to organs.

H373 May cause damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P311 IF exposed or concerned: Call a POISON

CENTER/ doctor. P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

May damage fertility. May damage the unborn child. May cause damage to organs. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards

Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
oxyclozanide	2277-92-1	>= 30 -< 50
oxfendazole	53716-50-0	>= 20 -< 25
Starch, oxidized	65996-62-5	>= 10 -< 20
Magnesium stearate	557-04-0	>= 1 -< 10

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person. May damage fertility. May damage the unborn child.

Most important symptoms and effects, both acute and

delayed

May cause damage to organs.

May cause damage to organs through prolonged or repeated

exposure.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

: First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment

when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Protection of first-aiders

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Chlorine compounds Nitrogen oxides (NOx)

Metal oxides

Oxides of phosphorus

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

7. HANDLING AND STORAGE

Handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust.

Do not swallow. Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety

practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
oxyclozanide	2277-92-1	TWA	0.4 mg/m3 (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm ²	Internal
Starch, oxidized	65996-62-5	TWA (inhal- able dust)	0.5 mg/m3	ACGIH

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2024/04/06

 4.0
 2024/09/28
 7942506-00009
 Date of first issue: 2021/03/19

Magnesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m3	ACGIH
		TWA (Respirable particulate matter)	3 mg/m3	ACGIH

Engineering measures : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

Appearance : powder

Colour : white to off-white, light cream, cream

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : 0.88 g/cm³

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 7942506-00009 4.0 2024/09/28 Date of first issue: 2021/03/19

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid Heat, flames and sparks.

Avoid dust formation. Oxidizing agents

Incompatible materials

Hazardous decomposition

products

: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes Inhalation

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

: Acute toxicity estimate: > 5,000 mg/kg Acute oral toxicity

Method: Calculation method

Components:

oxyclozanide:

Acute oral toxicity LD50 (Rat): 3,519 mg/kg

Target Organs: Central nervous system

Acute toxicity (other routes of : LDLo (sheep): 10 mg/kg

administration)

Application Route: Intravenous

oxfendazole:

LD50 (Rat): > 6,000 mg/kgAcute oral toxicity

LD50 (Dog): 1,600 mg/kg

LD50 (sheep): 250 mg/kg

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icitv

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

oxyclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rabbit

Result : No skin irritation

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

oxyclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rabbit

Result : No eye irritation

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 7942506-00009 4.0 2024/09/28 Date of first issue: 2021/03/19

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

oxyclozanide:

Exposure routes Dermal

Remarks Not classified due to lack of data.

Magnesium stearate:

: Maximisation Test Test Type Exposure routes Skin contact : Guinea pig Species

: OECD Test Guideline 406 Method

Result negative

Remarks Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

oxyclozanide:

Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: positive

Test Type: Mouse Lymphoma

Result: positive

Genotoxicity in vivo Test Type: Micronucleus test

> Species: Mouse **Application Route: Oral** Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Application Route: Oral Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

П

oxfendazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse Application Route: Oral

Result: positive

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

oxyclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rat
Application Route : Oral
Exposure time : 1 Years

Symptoms : No adverse effects

Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years

Symptoms : No adverse effects

Target Organs : Liver

Reproductive toxicity

May damage fertility. May damage the unborn child.

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

Components:

oxyclozanide:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat, male and female

Application Route: Oral

General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofoetal

and postnatal development Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body

weight

Symptoms: Reduced body weight, No effects on embryofoetal

and postnatal development Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: LOAEL: 75 - 100 mg/kg body

weight

Result: No fetotoxicity, No teratogenic effects

Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body

weight

Result: No fetotoxicity, No teratogenic effects, No effects on

fertility

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 200 mg/kg body weight

Result: No fetotoxicity, No teratogenic effects

Test Type: Development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 100 mg/kg body weight

Result: No fetotoxicity, No teratogenic effects

Test Type: Development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: NOAEL: 32 mg/kg body weight

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

Result: Fetotoxicity, Skeletal malformations

Reproductive toxicity - As-

sessment

: Suspected of damaging the unborn child.

oxfendazole:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 17 mg/kg body weight

Target Organs: Testes Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0.9 mg/kg body weight

Target Organs: Liver

Result: No effects on fertility

Test Type: Fertility Species: Mouse Application Route: Oral

Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight

Target Organs: Testes Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: positive, Fetal effects

Test Type: Embryo-foetal development

Species: Rat

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: positive, Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Mouse Application Route: Oral

Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-foetal toxicity, foetal abnormalities

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 0.625 mg/kg body weight

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

effects on development, based on animal experiments.

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

STOT - single exposure

May cause damage to organs.

Components:

oxyclozanide:

Exposure routes : Oral

Target Organs : Central nervous system
Assessment : May cause damage to organs.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

oxyclozanide:

Target Organs : Brain, Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

oxfendazole:

Exposure routes : Oral

Target Organs : Liver, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

oxyclozanide:

Species : Rat

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

NOAEL : 9 mg/kg
LOAEL : 44.5 mg/kg
Application Route : Oral
Exposure time : 3 Months

Target Organs : Brain, Liver, spleen, Adrenal gland

Symptoms : Liver effects

Species: DogNOAEL: 5 mg/kgLOAEL: 25 mg/kgApplication Route: OralExposure time: 3 MonthsTarget Organs: Brain, Liver

Symptoms : blood effects, alteration in liver enzymes

oxfendazole:

Species : Rat

NOAEL : 11 mg/kg

Application Route : Oral

Exposure time : 2 Weeks

Target Organs : Blood, Liver, Testis

Species : Rat

NOAEL : 3.8 mg/kg

Application Route : Oral

Exposure time : 3 Months

Target Organs : Liver, Testis

Species : Mouse
NOAEL : 750 mg/kg
Application Route : Oral
Exposure time : 1 Months
Target Organs : Liver

Species : Mouse
NOAEL : 37.5 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Liver

Species : Dog
NOAEL : 6 mg/kg
Application Route : Oral
Exposure time : 1 Months

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 11 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Target Organs : Lymph nodes, thymus gland

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

Species : Dog

NOAEL : 13.5 mg/kg
Application Route : Oral
Exposure time : 12 Months
Target Organs : Liver

Starch, oxidized:

Species : Rat

NOAEL : 22,500 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:

oxyclozanide:

Not applicable

Experience with human exposure

Components:

oxyclozanide:

Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central

nervous system depression

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

oxyclozanide:

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 0.69 mg/l

aquatic invertebrates Exposure time: 48 h

Method: OECD Test Guideline 202

M-Factor (Acute aquatic tox- : 1

icity)

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

M-Factor (Chronic aquatic

toxicity)

oxfendazole:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l

Exposure time: 96 h

LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l

Exposure time: 96 h

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.059 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 4

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): > 4

mg/l

10

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- :

icity)

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.023 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

: 1

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other:

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Persistence and degradability

Components:

oxyclozanide:

Stability in water : Hydrolysis: 50 %(156 d)

Method: OECD Test Guideline 111

oxfendazole:

Stability in water : Hydrolysis: < 5 %(4 d)

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

oxyclozanide:

Partition coefficient: n- : log Pow: 3.99

octanol/water pH: 7

Method: OECD Test Guideline 107

oxfendazole:

Partition coefficient: n- : log Pow: 1.95

octanol/water

Magnesium stearate:

Partition coefficient: n- : log Pow: > 4

octanol/water

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

Mobility in soil

Components:

oxyclozanide:

Distribution among environ-

mental compartments

log Koc: 4.83

Method: OECD Test Guideline 106

oxfendazole:

Distribution among environ-

mental compartments

log Koc: 3.2

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxfendazole, oxyclozanide)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(oxfendazole, oxyclozanide)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

Packing instruction (passen-

ger aircraft)

ssen- : 956

956

Environmentally hazardous : yes

19/22

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

IMDG-Code

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxfendazole, oxyclozanide)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

GB 6944/12268

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(oxfendazole, oxyclozanide)

Class : 9
Packing group : III
Labels : 9
Marine pollutant : no

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals : This product is not listed in the cata-

logue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of de-

termination.

Identification of Major Hazard Installations for Hazardous Chemicals (GB : Not listed

18218)

Hazardous Chemicals for Priority Management under : Not listed

SAWS

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import : Not listed

and Export

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2024/09/28

Further information

Sources of key data used to

compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA

according to GB/T 16483 and GB/T 17519



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 4.0 2024/09/28 7942506-00009 Date of first issue: 2021/03/19

- International Air Transport Association: IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States): UN - United Nations: UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN